A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Test Article or Placebo Administered Orally to Healthy and Osteoarthritis Subjects.

Wyeth is now a wholly owned subsidiary of Pfizer0 sitesJuly 2006

ConditionsHealthy Subjects Osteoarthritis

DrugsAGG-523

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Healthy Subjects
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Primary Endpoint: Assess the safety of multiple doses of AGG-523 administered to subjects.
Status: Completed
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the safety and tolerbility of ascending multiple oral doses of AGG-523 in healthy subjects and in subjects with osteoarthritis.

Registry

clinicaltrials.gov

Start Date

July 2006

End Date

February 2007

Last Updated

18 years ago

Study Type

Interventional

Study Design

Factorial

Sex

All

Investigators

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

•Healthy men or women, aged 18 to 40 years and subjects with osteoarthritis of the knee, aged 40 to 75 years.
•Women must be of non-childbearing potential, defined as surgically sterile with documentation of ultrasound.
•Must be nonsmoker or smoke less than 10 cigarettes per day.